Arcutis Biotherapeutics, Inc. (ARQT) - Stock Analysis
Last updated: Mar 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High gross margins ⢠Strong liquidity ⢠Full-year loss ARQT combines exceptionally high gross margins and strong liquidity with a profitable quarter but faces fullâyear operating losses, heavy operating expenses, meaningful leverage, a large accumulated deficit, and rich market multiples.
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Below short-term mean ⢠Support cluster Support Level: $23.60 Resistance Level: $26.50â$28.60 Over the last month the stock fell from $26.07 to $24.00 (â7.9%), trading ~9â10% below its last-month mean with near-term support at $23.60 (intraday lows $23.97â$24.12) and resistance $26.50â$28.60, where a decisive break below $23.60 would signal further downside while rallies are likely capped in the midâhigh $20s.
Sentiment & News
Key News Insights: ⢠Strong ZORYVE sales ⢠Pediatric sNDA path ⢠Analyst caution Arcutis delivered strong Q4/FY results and raised 2026 guidance on robust ZORYVE sales and pediatric data supporting an upcoming sNDA, while investors temper expectations after a recent run and analyst downgrade.
AI Summary
Arcutis has shifted from a development-stage, binary biotech to an early commercial growth company where sustaining consecutive quarters of positive operating cash flow and continued ZORYVE script momentum â plus a timely pediatric sNDA â are now the primary value drivers. The key actionable risk: heavy reliance on a single product and potential grossâtoânet/payor normalization that could rapidly compress margins and valuation, so monitor quarterly cash flow durability, script trends, and pediatric approval timing closely.
Description
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company developing topical treatments for dermatological conditions. Its lead asset is a roflumilast cream that has completed Phase III trials for plaque psoriasis and atopic dermatitis, and its pipeline includes additional roflumilast and topical JAK1 inhibitor formulations targeting scalp and skin disorders such as seborrheic dermatitis, hand eczema, vitiligo and alopecia areata. The company was incorporated in 2016, changed its name in October 2019, and is headquartered in Westlake Village, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 4 | Mar 11 | ARQT | Arcutis Biotherapeutics, Inc. | Catalyst-rich dermatology name: strong recent ZORYVE revenue, raised 2026 sales guidance, and guidance for continued positive operating cash flow are coupled with a pediatric sNDA filing expected in Q2 2026 and early ARQ-234 Phase 1 progress; despite current technical weakness, any sNDA/regulatory or cash-flow update in the next few days could trigger a sharp rebound from oversold levels. | Closed | -0.7% |
| Dec 2 | Dec 9 | ARQT | Arcutis Biotherapeutics, Inc. | Compelling short-term growth supported by strong Q3 revenue growth (+122% YoY), recent FDA pediatric approvals, upcoming Phase 2 topline data in Q1 2026, solid profitability trends, strong liquidity with $191M cash, and a 20% price surge with bullish technical momentum. | Closed | +1.1% |